You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Janssen Prods Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Janssen Prods
International Patents:787
US Patents:23
Tradenames:7
Ingredients:6
NDAs:8

Drugs and US Patents for Janssen Prods

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Exclusivity Expiration
Janssen Prods OLYSIO simeprevir sodium CAPSULE;ORAL 205123-001 Nov 22, 2013 DISCN Yes No 9,623,022 ⤷  Subscribe ⤷  Subscribe
Janssen Prods OLYSIO simeprevir sodium CAPSULE;ORAL 205123-001 Nov 22, 2013 DISCN Yes No 8,741,926 ⤷  Subscribe Y ⤷  Subscribe
Janssen Prods PREZISTA darunavir TABLET;ORAL 021976-001 Jun 23, 2006 DISCN Yes No 7,700,645*PED ⤷  Subscribe Y ⤷  Subscribe
Janssen Prods PREZISTA darunavir TABLET;ORAL 021976-004 Dec 18, 2008 RX Yes No 7,700,645*PED ⤷  Subscribe Y ⤷  Subscribe
Janssen Prods PREZISTA darunavir TABLET;ORAL 021976-003 Oct 21, 2008 DISCN Yes No 8,518,987*PED ⤷  Subscribe Y ⤷  Subscribe
Janssen Prods SYMTUZA cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 210455-001 Jul 17, 2018 RX Yes Yes 9,296,769 ⤷  Subscribe Y Y ⤷  Subscribe
Janssen Prods YONDELIS trabectedin POWDER;INTRAVENOUS 207953-001 Oct 23, 2015 RX Yes Yes 8,895,557*PED ⤷  Subscribe Y ⤷  Subscribe
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Exclusivity Expiration
Showing 1 to 7 of 7 entries

Expired US Patents for Janssen Prods

ApplicantTradenameGeneric NameDosageNDAApproval DatePatent No.Patent Expiration
Janssen Prods PREZCOBIX cobicistat; darunavir TABLET;ORAL 205395-001 Jan 29, 2015 RE43802*PED ⤷  Subscribe
Janssen Prods PREZISTA darunavir TABLET;ORAL 021976-003 Oct 21, 2008 6,248,775*PED ⤷  Subscribe
Janssen Prods PREZISTA darunavir TABLET;ORAL 021976-002 Feb 25, 2008 8,597,876*PED ⤷  Subscribe
Janssen Prods PREZISTA darunavir TABLET;ORAL 021976-003 Oct 21, 2008 8,518,987*PED ⤷  Subscribe
Janssen Prods PREZISTA darunavir TABLET;ORAL 021976-006 Nov 9, 2012 RE43596*PED ⤷  Subscribe
Janssen Prods SYMTUZA cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 210455-001 Jul 17, 2018 7,803,788 ⤷  Subscribe
Janssen Prods SYMTUZA cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 210455-001 Jul 17, 2018 9,889,115 ⤷  Subscribe
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>Patent No.>Patent Expiration
Showing 1 to 7 of 7 entries
Paragraph IV (Patent) Challenges for JANSSEN PRODS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 800 mg ➤ Subscribe 2013-05-14

International Patents for Janssen Prods Drugs

CountryPatent NumberEstimated Expiration
Croatia P20161502 ⤷  Subscribe
Japan 2011236221 ⤷  Subscribe
Montenegro 02582 ⤷  Subscribe
Portugal 1713823 ⤷  Subscribe
Taiwan I315199 ⤷  Subscribe
Taiwan I444367 ⤷  Subscribe
Ukraine 92467 ⤷  Subscribe
>Country>Patent Number>Estimated Expiration
Showing 1 to 7 of 7 entries

Supplementary Protection Certificates for Janssen Prods Drugs

Patent NumberSupplementary Protection CertificateSPC CountrySPC ExpirationSPC Description
1663240 122015000088 Germany ⤷  Subscribe PRODUCT NAME: KOMBINATION VON RILPIVIRIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ VON RILPIVIRIN, EINSCHLIESSLICH DES HYDROCHLORIDSALZES VON RILPIVIRIN, TENOFOVIR, INSBESONDERE TENOFOVIRDISOPROXILFUMARAT, UND EMTRICITABIN; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128
1632232 122016000111 Germany ⤷  Subscribe PRODUCT NAME: KOMBINATION VON RILPIVIRINHYDROCHLORID ODER EINER THERAPEUTISCH AEQUIVALENTEN, DURCH DAS GRUNDPATENT GESCHUETZTEN FORM DAVON, EMTRICITABIN UND TENOFOVIRALAFENAMID ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ DAVON, INSBESONDERE TENOFOVIRALAFENAMIDFUMARAT; REGISTRATION NO/DATE: EU/1/16/1112 20160621
2487163 1790002-8 Sweden ⤷  Subscribe PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND ATAZANAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR ATAZANAVIR SULFATE; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/15/1025, 2015-07-15
2932970 1890039-9 Sweden ⤷  Subscribe PRODUCT NAME: DOLUTEGRAVIR SODIUM + RILPIVIRINE HYDROCHLORIDE; REG. NO/DATE: EU/1/18/1282 20180518
2487162 CA 2017 00002 Denmark ⤷  Subscribe PRODUCT NAME: COBICISTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF OG DARUNAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, ISAER DARUNAVIRETHANOLAT; REG. NO/DATE: EU/1/14/967/001 20141121
2049506 PA2015040 Lithuania ⤷  Subscribe PRODUCT NAME: COBICISTATUM; REGISTRATION NO/DATE: EU/1/13/830/001 - 002 20130524
2487166 PA2016038,C2487166 Lithuania ⤷  Subscribe PRODUCT NAME: KOBICISTATAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA IR TENOFOVIRO ALAFENAMIDAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, YPAC TENOFOVIRO ALAFENAMIDO FUMARATAS; REGISTRATION NO/DATE: EU/1/15/1061 20151119
>Patent Number>Supplementary Protection Certificate>SPC Country>SPC Expiration>SPC Description
Showing 1 to 7 of 7 entries
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.